AR079661A1 - Derivados de n-(4f-3-{1-[indol-3-carbonil]piperidin-4-il}bencil)acetamidas - Google Patents

Derivados de n-(4f-3-{1-[indol-3-carbonil]piperidin-4-il}bencil)acetamidas

Info

Publication number
AR079661A1
AR079661A1 ARP100104817A ARP100104817A AR079661A1 AR 079661 A1 AR079661 A1 AR 079661A1 AR P100104817 A ARP100104817 A AR P100104817A AR P100104817 A ARP100104817 A AR P100104817A AR 079661 A1 AR079661 A1 AR 079661A1
Authority
AR
Argentina
Prior art keywords
compound
hydrogen
compounds
inflammatory diseases
group
Prior art date
Application number
ARP100104817A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR079661A1 publication Critical patent/AR079661A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)

Abstract

Composiciones para el tratamiento y mejora de enfermedades inflamatorias. Específicamente, se refiere a compuestos que tienen actividad de inhibicion de triptasa y a los intermedios de estos, a composiciones farmacéuticas que comprenden dichos compuestos, y a un método para tratar a sujetos que padecen una condicion, enfermedad o trastorno que puede mejorar por la administracion de un inhibidor de triptasa incluyendo, pero sin limitarse a, por ejemplo, asma y otras enfermedades inflamatorias incluyendo la degeneracion macular aguda. Reivindicacion 1: Un compuesto de la formula (I) en el que: X e Y se seleccionan del grupo que consiste en hidrogeno, metilo, fluor, cloro, trifluorometilo, metoxi, trifluorometoxi, morfolin-4-il-metanona de manera que dos de los sustituyentes no son hidrogeno al mismo tiempo; R1 es H, alquilo inferior o alquilo sustituido; R2 se selecciona del grupo que comprende hidrogeno y aminoácidos naturales y no naturales; un N-oxido de dicho compuesto, una sal farmacéuticamente aceptable de dicho compuesto, un solvato de dicho compuesto o un hidrato de dicho compuesto.
ARP100104817A 2009-12-23 2010-12-21 Derivados de n-(4f-3-{1-[indol-3-carbonil]piperidin-4-il}bencil)acetamidas AR079661A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28953709P 2009-12-23 2009-12-23
FR1057197 2010-09-10

Publications (1)

Publication Number Publication Date
AR079661A1 true AR079661A1 (es) 2012-02-08

Family

ID=44246892

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104817A AR079661A1 (es) 2009-12-23 2010-12-21 Derivados de n-(4f-3-{1-[indol-3-carbonil]piperidin-4-il}bencil)acetamidas

Country Status (26)

Country Link
US (1) US8710080B2 (es)
EP (1) EP2516418B1 (es)
JP (1) JP2013515732A (es)
KR (1) KR20120106824A (es)
CN (1) CN102791702A (es)
AR (1) AR079661A1 (es)
AU (1) AU2010333772B2 (es)
BR (1) BR112012014860A2 (es)
CA (1) CA2784891A1 (es)
CY (1) CY1115445T1 (es)
DK (1) DK2516418T3 (es)
ES (1) ES2481790T3 (es)
HK (1) HK1178517A1 (es)
HR (1) HRP20140607T1 (es)
IL (1) IL220380A0 (es)
MX (1) MX2012006739A (es)
MY (1) MY155980A (es)
PL (1) PL2516418T3 (es)
PT (1) PT2516418E (es)
RS (1) RS53456B (es)
RU (1) RU2012131146A (es)
SG (1) SG181501A1 (es)
SI (1) SI2516418T1 (es)
TW (1) TW201125860A (es)
UY (1) UY33134A (es)
WO (1) WO2011079095A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2516418T3 (da) 2009-12-23 2014-08-11 Sanofi Sa Pro-drugs af [4[4-(5-aminomethyl-2-fluor-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanoner og syntese deraf
CA2784894A1 (en) * 2009-12-23 2011-06-30 Sanofi Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4879119A (en) 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
WO1993011938A1 (en) 1991-12-18 1993-06-24 Minnesota Mining And Manufacturing Company Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
HU227630B1 (hu) * 2000-05-22 2011-10-28 Aventis Pharma Inc Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények
GB0012362D0 (en) 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
NZ591234A (en) * 2008-08-22 2012-03-30 Sanofi Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
DK2516418T3 (da) 2009-12-23 2014-08-11 Sanofi Sa Pro-drugs af [4[4-(5-aminomethyl-2-fluor-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanoner og syntese deraf

Also Published As

Publication number Publication date
HRP20140607T1 (hr) 2014-09-26
BR112012014860A2 (pt) 2016-03-29
SG181501A1 (en) 2012-07-30
PL2516418T3 (pl) 2014-10-31
IL220380A0 (en) 2012-08-30
SI2516418T1 (sl) 2014-08-29
TW201125860A (en) 2011-08-01
AU2010333772A1 (en) 2012-07-05
WO2011079095A1 (en) 2011-06-30
KR20120106824A (ko) 2012-09-26
AU2010333772B2 (en) 2016-07-14
MY155980A (en) 2015-12-31
RU2012131146A (ru) 2014-02-10
DK2516418T3 (da) 2014-08-11
JP2013515732A (ja) 2013-05-09
PT2516418E (pt) 2014-07-18
MX2012006739A (es) 2012-06-28
HK1178517A1 (en) 2013-09-13
UY33134A (es) 2011-07-29
ES2481790T3 (es) 2014-07-31
RS53456B (en) 2014-12-31
CN102791702A (zh) 2012-11-21
EP2516418B1 (en) 2014-05-14
EP2516418A1 (en) 2012-10-31
US20120238573A1 (en) 2012-09-20
CA2784891A1 (en) 2011-06-30
CY1115445T1 (el) 2017-01-04
US8710080B2 (en) 2014-04-29

Similar Documents

Publication Publication Date Title
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
ATE517882T1 (de) Chinolinderivate
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201001159A1 (ru) Конденсированные гетероциклические производные и их применение
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
EA201270546A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA200970856A1 (ru) Ингибиторы пути хеджхога
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201170607A1 (ru) Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
RU2011127451A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА
CO6300945A2 (es) Compuestos fenil ftalazin - 1l piperidin - 4 - il benzamida o sales farmaceuticamente aceptables de los mismos, utiles como antagonistas de la trayectoria hedgehoc (hh)
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина

Legal Events

Date Code Title Description
FB Suspension of granting procedure